# A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals

> **NIH NIH U19** · STANFORD UNIVERSITY · 2022 · $161,924


## Key facts

- **NIH application ID:** 10546082
- **Project number:** 5U19AI104209-09
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** R. Sharon Chinthrajah
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $161,924
- **Award type:** 5
- **Project period:** 2013-07-01 → 2024-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10546082

## Citation

> US National Institutes of Health, RePORTER application 10546082, A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals (5U19AI104209-09). Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/grant/nih/10546082. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*